These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 25168947)

  • 81. Perioperative hemostatic management of patients treated with vitamin K antagonists.
    Levy JH; Tanaka KA; Dietrich W
    Anesthesiology; 2008 Nov; 109(5):918-26. PubMed ID: 18946305
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Potential antidotes for reversal of old and new oral anticoagulants.
    Suryanarayan D; Schulman S
    Thromb Res; 2014 May; 133 Suppl 2():S158-66. PubMed ID: 24862137
    [TBL] [Abstract][Full Text] [Related]  

  • 83. New oral anticoagulants--what the cardiothoracic surgeon needs to know.
    Kaneko T; Yammine M; Aranki SF
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):1794-1801.e1. PubMed ID: 24973923
    [No Abstract]   [Full Text] [Related]  

  • 84. Treatment of bleeding complications in patients on anticoagulant therapy.
    Piran S; Schulman S
    Blood; 2019 Jan; 133(5):425-435. PubMed ID: 30559261
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Bleeding complications of targeted oral anticoagulants: what is the risk?
    Levine M; Goldstein JN
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):504-9. PubMed ID: 25696901
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.
    Raimondi P; Hylek EM; Aronis KN
    Curr Pharm Des; 2017; 23(9):1406-1423. PubMed ID: 27917717
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
    Dickneite G
    Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Anticoagulant Reversal and Anesthetic Considerations.
    Meltzer J; Guenzer JR
    Anesthesiol Clin; 2017 Jun; 35(2):191-205. PubMed ID: 28526142
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Indications for administration of fresh frozen plasma and clotting factor concentrates.
    Muntean W
    Acta Anaesthesiol Scand Suppl; 1996; 109():139-41. PubMed ID: 8901985
    [No Abstract]   [Full Text] [Related]  

  • 91. Prothrombin complex concentrates: clinical use.
    Menache D
    Ann N Y Acad Sci; 1981; 370():747-56. PubMed ID: 6791551
    [No Abstract]   [Full Text] [Related]  

  • 92. Different Heparin Contents in Prothrombin Complex Concentrates May Impair Blood Clotting in Outpatients With Ventricular Assist Devices Receiving Phenprocoumon.
    Felli A; Zeidler P; Jilma B; Opfermann P; Holaubek C; Zimpfer D; Wadowski PP; Steinlechner B
    J Cardiothorac Vasc Anesth; 2016 Jan; 30(1):96-101. PubMed ID: 26613641
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [EMERGENCY TREATMENT OF BLEEDING IN PATIENTS TAKING WARFARIN].
    Prasolov NV; Shulutko EM; Bulanov AY; Yatskov KV; Shcherbakov OV
    Anesteziol Reanimatol; 2015; 60(2):72-6. PubMed ID: 26148369
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [6-years' experience with the clinical use of the hemostatic preparation, PPSB].
    Koniukhov SG; Saltykova ZA; Tarasova LN
    Probl Gematol Pereliv Krovi; 1977 Aug; 22(8):37-40. PubMed ID: 928338
    [No Abstract]   [Full Text] [Related]  

  • 95. Activated prothrombin concentrate for patients with factor VIII inhibitors.
    Kurczynski EM; Penner JA
    N Engl J Med; 1974 Jul; 291(4):164-7. PubMed ID: 4834485
    [No Abstract]   [Full Text] [Related]  

  • 96. Management of Christmas disease and Stuart-Prower deficiency with a prothrombin-complex concentrate (factors II, VII, IX, X).
    Tullis JL; Melin M
    Bibl Haematol; 1968; 29():1134-9. PubMed ID: 5700309
    [No Abstract]   [Full Text] [Related]  

  • 97. Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal.
    Kinard TN; Sarode R
    Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):417-27. PubMed ID: 24650310
    [TBL] [Abstract][Full Text] [Related]  

  • 98. New oral anticoagulants in severe trauma patients: enemy at the gates?
    Egea-Guerrero JJ; Quintana Díaz M
    Med Intensiva; 2015 Apr; 39(3):167-71. PubMed ID: 25510394
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Doerr B; Mueller-Cohrs J; Pragst I; Morishima Y; Dickneite G
    Anesthesiology; 2015 Feb; 122(2):387-98. PubMed ID: 25419685
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Letter: Factor VIII inhibitor following surgery for epidural hemorrhage in hemophilia: successful therapy with a concentrate containing factors II, VII, IX, and X.
    Goodknight SH; Common HH; Lovrein EW
    J Pediatr; 1976 Feb; 88(2):356-7. PubMed ID: 1249702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.